BerGenBio

Selective AXL inhibitors

Home  /  Events  /  BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020

BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020

Share This Post

Add to Calendar 01/29/2021 08:00 AM Europe/Oslo BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020 For more information visit: https://www.bergenbio.com/bergenbio-to-present-updates-from-ongoing-phase-ii-bemcentinib-combination-study-in-refractory-nsclc-at-wclc-2020/

Date: 29th January 2021

Time: 09.50 AM Singapore Time / 02.50 AM CET

Title: A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC

Presenting Author: Dr. Matthew G. Krebs PhD.

Session/Abstract ID: Immunotherapy (Phase II/III Trials) # 3647

The presentation can be found at www.bergenbio.com under Investors / Presentations

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.